LITS
Lite Strategy, Inc.
There isn't enough reported data to score LITS yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LITS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| Unavailable | |
| Strong |
LITS's balance sheet is currently strong, and its profitability is stable, but its revenue is weak. There isn't enough data to rate its cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LITS PE Valuation
LITS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LITS Forward outlook
There aren't enough analyst estimates for LITS to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
LITS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.46 | -$0.15 |
| Q2 2026 | -$2.06 | +$0.33 |
| Q1 2026 | -$2.00 | +$2.75 |
| Q4 2025 | -$1.73 | +$4.00 |
| Q3 2025 | -$1.31 | +$5.68 |
| Q2 2025 | -$2.39 | -190% |
| Q1 2025 | -$4.75 | -226% |
| Q4 2024 | -$5.73 | -303% |
LITS is still losing money, but far less than before: $1.46 per share over the past year, against $14.80 at its worst in early 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over LITS on earnings quality, reporting a profit while its opponent remains loss making.
LITS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $65.3M | +648% |
| Q2 2023 | $1.5M | -87% |
| Q1 2023 | $5.9M | -39% |
| Q4 2022 | $32.7M | +177% |
| Q3 2022 | $8.7M | +13% |
| Q2 2022 | $11.4M | -41% |
| Q1 2022 | $9.7M | +301% |
| Q4 2021 | $11.8M | +29% |
LITS's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | 85% | +293 points |
| Q2 2023 | -760% | -619 points |
| Q1 2023 | -278% | -56 points |
| Q4 2022 | 27% | +176 points |
| Q3 2022 | -209% | +51 points |
| Q2 2022 | -142% | -124 points |
| Q1 2022 | -222% | +691 points |
| Q4 2021 | -149% | +61 points |
LITS's operating margin was 85% last quarter, up 293 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
LITS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.2M | +$2.3M |
| Q2 2026 | -$1.2M | +$1.3M |
| Q1 2026 | -$1.5M | +$1.7M |
| Q3 2025 | -$4.5M | +$6.9M |
| Q2 2025 | -$2.5M | +$15.5M |
| Q1 2025 | -$3.3M | -$339K |
| Q3 2024 | -$11.5M | +$7M |
| Q2 2024 | -$18M | -$6.7M |
LITS has burned cash in almost every quarter: −$7M over the past year, against −$22M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LITS on cash generation, producing positive trailing cash flow while its opponent burns cash.
LITS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4% | -1.4M shares |
| 1 year | +13% | +3.7M shares |
| 3 years | +398% | +26.5M shares |
| 5 years | +483% | +27.5M shares |
| Available history | +744% | +29.3M shares |
LITS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.4M |
| Q2 2026 | $2.9M |
| Q1 2026 | $1.8M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LITS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | -0.3x | Net Cash |
| Q1 2024 | -0.1x | Net Cash |
| Q4 2023 | -0.3x | Net Cash |
| Q3 2023 | -0.1x | Net Cash |
LITS has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
LITS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 24.0 | Neutral |
LITS's weekly RSI is 40 (neutral) and its Stochastic is 24 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LITS PE vs Healthcare Sector
| Metric | LITS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LITS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LITS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.18 | 23% below |
| 20 week MA | $1.07 | 15% below |
| 50 week MA | $1.14 | 20% below |
| 100 week MA | $1.98 | 54% below |
| 200 week MA | $3.41 | 73% below |
LITS is in a downtrend: it's below all five of its weekly moving averages, and 73% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LITS on trend strength, trading above more of its moving averages.
LITS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.4 | $58.0 | +34% |
| 2021 | $58.0 | $51.4 | -11% |
| 2022 | $51.4 | $5.00 | -90% |
| 2023 | $5.00 | $5.80 | +16% |
| 2024 | $5.80 | $2.44 | -58% |
| 2025 | $2.44 | $1.35 | -45% |
| 2026 YTD | $1.35 | $0.91 | -33% |
LITS has finished lower in four of the last six years. It's down 33% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LITS on returns for 2026, with the stronger performance.